参考文献/References:
[1] Guardia-Laguarta C, Area-Gomez E, Rub C, et al. alpha-
Synuclein is localized to mitochondria-associated ER mem-
branes [J]. J Neurosci, 2014, 34(1): 249-259.
[2] Chen RH, Wislet-Gendebien S, Samuel F, et al. alpha-
Synuclein membrane association is regulated by the Rab3a
recycling machinery and presynaptic activity [J]. J Biol
Chem, 2013, 288(11): 7438-7849.
[3] DeWitt DC, Rhoades E. alpha-Synuclein can inhibit
SNARE-mediated vesicle fusion through direct interactions
with lipid bilayers [J]. Biochemistry, 2013, 52(14): 2385-
2387.
[4] Nakamura K, Nemani VM, Azarbal F, et al. Direct mem-
brane association drives mitochondrial fission by the Park-
inson disease-associated protein alpha-synuclein [J]. J
Biol Chem, 2011, 286(23): 20710-20726.
[5] Thayanidhi N, Helm JR, Nycz DC, et al. Alpha-synuclein
delays endoplasmic reticulum (ER)-to-Golgi transport in
mammalian cells by antagonizing ER/Golgi SNAREs [J].
Mol Biol Cell, 2010, 21(11): 1850-1863.
[6] Martinez-Vicente M, Vila M. Alpha-synuclein and protein
degradation pathways in Parkinson's disease: a pathological
feed-back loop [J]. Exp Neurol, 2013, 247: 308-313.
[7] Toppmeyer D, Seidman AD, Pollak M, et al. Safety and
efficacy of the multidrug resistance inhibitor Incel
(biricodar; VX-710) in combination with paclitaxel for
advanced breast cancer refractory to paclitaxel [J]. Clin
Cancer Res, 2002, 8(3): 670-678.
[8] 李 妍，孙黎光，吕世杰. α-突触核蛋白的细胞毒性作用
[J]. 生命的化学，2007，27（6）：503-505.
[9] Hassin-Baer S, Laitman Y, Azizi E, et al. The leucine rich
repeat kinase 2 (LRRK2) G2019S substitution mutation:
association with Parkinson disease, malignant melanoma
and prevalence in ethnic groups in Israel [J]. J Neurol, 2009,
256(3): 483-487.
[10] Lewis PA, Manzoni C. LRRK2 and human disease: a com-
plicated question or a question of complexes [J]. Sci Signal,
2012, 5(207): pe2.
[11] Tayebi N, Walker J, Stubblefield B, et al. Gaucher disease
with parkinsonian manifestations: does glucocerebrosidase
deficiency contribute to a vulnerability to parkinsonism [J].
Mol Genet Metab, 2003, 79(2): 104-109.
[12] Neumann J, Bras J, Deas E, et al. Glucocerebrosidase
mutations in clinical and pathologically proven Parkinson's
disease [J]. Brain, 2009, 132(Pt 7): 1783-1794.
[13] Winder-Rhodes SE, Evans JR, Ban M, et al. Glucocerebro-
sidase mutations influence the natural history of Parkinson's
disease in a community-based incident cohort [J]. Brain,
2013, 136(Pt 2): 392-399.
[14] Parkinson Study Group CALM Cohort Investigators. Long-
term effect of initiating pramipexole vs levodopa in early
Parkinson disease [J]. Arch Neurol, 2009, 66(5): 563-570.
[15] Olanow CW, Rascol O, Hauser R, et al. A double-blind,
delayed-start trial of rasagiline in Parkinson's disease [J].
N Engl J Med, 2009, 361(13): 1268-1278.
[16] National Collaborating Centre for Chronic Conditions (UK).
Parkinson's Disease: National Clinical Guideline for Diag-
nosis and Management in Primary and Secondary Care [M].
London: Royal College of Physicians (UK), 2006.
[17] Rodriguez-Oroz MC, Moro E, Krack P. Long-term outcomes
of surgical therapies for Parkinson's disease [J]. Mov Disord,
2012, 27(14): 1718-1728.
[18] El-Sadik AO. Potential sources of stem cells as a regenera-
tive therapy for Parkinson's disease [J]. Stem Cells Cloning,
2010, 3: 183-191.
[19] Fu YS, Cheng YC, Lin MY, et al. Conversion of human um-
bilical cord mesenchymal stem cells in Wharton's jelly to
dopaminergic neurons in vitro: potential therapeutic appli-
cation for Parkinsonism [J]. Stem Cells, 2006, 24(1): 115-
124.
[20] Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al.
Safety and immunological effects of mesenchymal stem cell
transplantation in patients with multiple sclerosis and
amyotrophic lateral sclerosis [J]. Arch Neurol, 2010, 67(10):
1187-1194.
相似文献/References:
[1]张 威 李 楠 张海红 马 磊 高金鉴 王学廉 高国栋.丘脑底核与苍白球内侧部电刺激术治疗帕金森病疗效的Meta分析[J].中国临床神经外科杂志,2015,(12):718.[doi:10.13798/j.issn.1009-153X.2015.12.005]
ZHANG Wei,LI Nan,ZHANG Hai-hong,et al.Meta-analysis of curative effects of electric stimulation of the globus pallidus and subthalamic nucleus on Parkinson disease[J].,2015,(11):718.[doi:10.13798/j.issn.1009-153X.2015.12.005]
[2]杜彦挺 综述 潘亚文 审校.Moyamoya病的诊断和治疗的研究进展[J].中国临床神经外科杂志,2015,(12):761.[doi:10.13798/j.issn.1009-153X.2015.12.021]
[3]陈 娟 张华楸 综述 雷 霆 审校.库欣病发病机制的研究进展[J].中国临床神经外科杂志,2015,(10):594.[doi:10.13798/j.issn.1009-153X.2015.10.006]
[4]欧阳佳 武广永 综述 刘如恩 审校.帕金森病基因治疗研究进展[J].中国临床神经外科杂志,2015,(03):187.[doi:10.13798/j.issn.1009-153X.2015.03.022]
[5]王米君 综述 舒 凯 审校.脑膜瘤瘤周水肿的研究现状[J].中国临床神经外科杂志,2015,(05):315.[doi:10.13798/j.issn.1009-153X.2015.05.022]
[6]陆丽娟,李玉凤,赵喜庆 综述,等.氯离子通道与胶质瘤的关系研究进展[J].中国临床神经外科杂志,2016,(12):803.[doi:10.13798/j.issn.1009-153X.2016.12.029]
[7]吴 超 于 涛 王振宇 段丽萍.脊髓损伤后神经源性肠功能障碍的发生机制[J].中国临床神经外科杂志,2017,(04):282.[doi:10.13798/j.issn.1009-153X.2017.04.030]
[8]吕艳霞 李安荣 杨朋磊 综述 胡钧涛 审校.炎症反应在颅内动脉瘤发生中作用的研究进展[J].中国临床神经外科杂志,2017,(05):363.[doi:10.13798/j.issn.1009-153X.2017.05.030]
[9]马 涛.颅脑损伤后凝血功能障碍的机制及干预措施[J].中国临床神经外科杂志,2017,(08):601.[doi:10.13798/j.issn.1009-153X.2017.08.030]
[10]陈礼道 柳 雯 张 捷 付 锴 张继波 刘学猛 彭启珍 丁 伟.脂质头皮标志物在脑深部电刺激术针道设计中的应用[J].中国临床神经外科杂志,2017,(09):619.[doi:10.13798/j.issn.1009-153X.2017.09.004]
CHEN Li-dao,LIU Wen,ZHANG Jie,et al.Application of lipid scalp markers to the design of electrode track for deep brain stimulation in patients with movement disorders[J].,2017,(11):619.[doi:10.13798/j.issn.1009-153X.2017.09.004]